Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines
Read
about Optimising potency and delivery: the new frontier of LNP in mRNA cancer vaccines
Acuitas takes majority stake in Montreal-based RNA construct manufacturer
Read
about Acuitas takes majority stake in Montreal-based RNA construct manufacturer
GEN Editors Reflect on Six of the Biggest Stories of the Year
Read
about GEN Editors Reflect on Six of the Biggest Stories of the Year
